Literature DB >> 27865610

Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.

Rodrigo Cristofoletti1, Nikunjkumar Patel2, Jennifer B Dressman3.   

Abstract

Postabsorptive factors which can affect systemic drug exposure are assumed to be dependent on the active pharmaceutical ingredient (API), and thus independent of formulation. In contrast, preabsorptive factors, for example, hypochlorhydria, might affect systemic exposure in both an API and a formulation-dependent way. The aim of this study was to evaluate whether the oral absorption of 2 poorly soluble, weakly basic APIs, ketoconazole (KETO) and posaconazole (POSA), would be equally sensitive to changes in dissolution rate under the following dosing conditions-coadministration with water, with food, with carbonated drinks, and in drug-induced hypochlorhydria. The systems-components of validated absorption and PBPK models for KETO and POSA were modified to simulate the above-mentioned clinical scenarios. Virtual bioequivalence studies were then carried out to investigate whether formulation effects on the plasma profile vary with the dosing conditions. The slow precipitation of KETO upon reaching the upper part of the small intestine renders its absorption more sensitive to the completeness of gastric dissolution and thus to the gastric environment than POSA, which is subject to extensive precipitation in response to a pH shift. The virtual bioequivalence studies showed that hypothetical test and reference formulations containing KETO would be bioequivalent only if the microenvironment in the stomach enables complete gastric dissolution. We conclude that physiologically based pharmacokinetic modeling and simulation has excellent potential to address issues close to bedside such as optimizing dosing conditions. By studying virtual populations adapted to various clinical situations, clinical strategies to reduce therapeutic failures can be identified.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biopharmaceutics Classification System; bioequivalence; disease states; dissolution; physiologically based pharmacokinetic modeling

Mesh:

Substances:

Year:  2016        PMID: 27865610     DOI: 10.1016/j.xphs.2016.10.008

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Utility of Physiologically Based Pharmacokinetic Absorption Modeling to Predict the Impact of Salt-to-Base Conversion on Prasugrel HCl Product Bioequivalence in the Presence of Proton Pump Inhibitors.

Authors:  Jianghong Fan; Xinyuan Zhang; Liang Zhao
Journal:  AAPS J       Date:  2017-07-14       Impact factor: 4.009

2.  Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model.

Authors:  Bart Hens; Arjang Talattof; Paulo Paixão; Marival Bermejo; Yasuhiro Tsume; Raimar Löbenberg; Gordon L Amidon
Journal:  AAPS J       Date:  2018-03-29       Impact factor: 4.009

Review 3.  In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.

Authors:  Fan Zhang; Ranran Jia; Huitao Gao; Xiaofei Wu; Bo Liu; Hongyun Wang
Journal:  Clin Pharmacokinet       Date:  2021-06-30       Impact factor: 5.577

4.  The Virtual Anemia Trial: An Assessment of Model-Based In Silico Clinical Trials of Anemia Treatment Algorithms in Patients With Hemodialysis.

Authors:  Doris H Fuertinger; Alice Topping; Franz Kappel; Stephan Thijssen; Peter Kotanko
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-01-31

5.  Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs.

Authors:  Zhongqi Dong; Jia Li; Fang Wu; Ping Zhao; Sue-Chih Lee; Lillian Zhang; Paul Seo; Lei Zhang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-07-31

6.  Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate.

Authors:  Nashid Farhan; Rodrigo Cristofoletti; Sumit Basu; Sarah Kim; Karthik Lingineni; Sibo Jiang; Joshua D Brown; Lanyan Lucy Fang; Lawrence J Lesko; Stephan Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.